Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase 2 Trial of AM0010 in Combination With Pembrolizumab vs. Pembrolizumab Alone as First-Line (1L) Therapy in Patients With Stage IV / Metastatic Wild Type (WT) Non-Small Cell Lung Cancer and Tumors With High Expression of PD-L1 (> 50%)

NCT03382899 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT03382899
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03382899 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase 2 Trial of AM0010 in Combination With Pembrolizumab vs. Pembrolizumab Alone as First-Line (1L) Therapy in Patients With Stage IV / Metastatic Wild Type (WT) Non-Small Cell Lung Cancer and Tumors With High Expression of PD-L1 (> 50%)
Lead sponsor
Eli Lilly and Company
Phase
Phase 2
Overall status
Terminated
Start date
March 19, 2018
Completion date
March 5, 2020
Enrollment
101 (actual)
Sites
74

Conditions

As the registry lists them; a condition with its own page is linked.

non small cell lung cancer